Who
Andrew C. Orth
President & CEO
Company insider
Files Form 4 as: President & CEO, City Therapeutics; Chief Commercial Officer, Krystal Biotech.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $1.6M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 31 May 2021
- Last trade
- 19 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 19 Oct 2026 | CTY City Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,979 at $0.00 | filing |
| 9 Jun 2023filed 9 Jun 2023 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 9 Jun 2023filed 9 Jun 2023 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Code M | $794K12,500 at $63.55 | filing |
| 9 Jun 2023filed 9 Jun 2023 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $674K5,261 at $128.10 | filing |
| 9 Jun 2023filed 9 Jun 2023 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $890K6,906 at $128.94 | filing |
| 9 Jun 2023filed 9 Jun 2023 | KRYS Krystal BiotechBiotechnology | SEC FORM 4 Sold | $43K333 at $129.70 | filing |
| 28 Feb 2023filed 28 Feb 2023 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 28 Feb 2023filed 28 Feb 2023 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 28 Feb 2022filed 1 Mar 2022 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 31 May 2021filed 2 Jun 2021 | KRYS Krystal Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —205,000 at $0.00 | filing |
News
Monte Rosa Therapeutics (NASDAQ:GLUE) versus Krystal Biotech (NASDAQ:KRYS) Head to Head SurveyKRYS · tickerreport.com · 21 Oct 2026Krystal Biotech Sees Broad Antitumor Activity With KB113 In Gorlin Syndrome; Stock UpKRYS · rttnews.com · 15 Oct 2026Krystal Biotech Reports Over 80% Lesion Regression With KB113 In Gorlin SyndromeKRYS · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name Andrew C. Orth; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.